Immunotherapy of Advanced Bladder Cancer - Daniel Petrylak

(Length of lecture - 38 minutes)

Daniel Petrylak, MD presents response rates and anti-tumor activity of checkpoint inhibition therapy in patients with advanced urothelial carcinoma and immunotherapy as initial therapy in cisplatin-ineligible patients and in patients with cisplatin pretreated disease.  Dr. Petrylak discusses trials that are on-going to explore immunotherapy based combinations and the use of immunotherapy in earlier stages of disease. 

Watch: Dr. Petryalk present: What is a checkpoint inhibitors and its mechanisms? What is a checkpoint inhibitors and its mechanisms?

Additional content on Immunotherapy of Advanced Bladder Cancer:

Watch - Immunotherapy in Bladder Cancer - Alan Bryce

Watch- Immunotherapy in Advanced Urothelial Cancer- Matthew Campbell

Immunotherapy of Advanced Bladder Cancer: The Next Frontier

EAU 2016 Immunotherapy for bladder cancer – benefits for all patients? - Session Highlights

Systemic Immunotherapy Bladder Cancer.. Get Ready! EVERYDAY UROLOGY- Full text article

Biography:
Daniel P Petrylak, MD. Professor of Medicine and Urology - Director, GU Translational Working Group, Co-Director, Signal Transduction Program Smilow Cancer Center, Yale University.
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe